澳洲8预测开奖结果-澳洲幸运8开奖结果168 The International Association for the Study of Lung Cancer
The IASLC is a global multidisciplinary organization dedicated to eradication of all forms of lung cancer. From provision of educational events around the world and virtually to research projects and publications that advance the science of lung cancer, the IASLC's members—consisting of medical, surgical, and radiation oncologists, as well as other thoracic oncology specialists such as nurses, basic scientists, pathologists, radiologists, pulmonologists, statisticians, patient research advocates, patients, and their caregivers—are raising the bar for care of patients with lung cancer.
In Focus
Lung Cancer Awareness Month
2022 IASLC Position Statement on Tobacco Cessation After a Cancer Diagnosis
Authored by the IASLC Tobacco Control & Smoking Cessation Committee
Tobacco use is a well-established cause of cancer and contributes to about 1 in 3 cancer deaths. Whereas the harmful effects of smoking on health are well recognized, the negative impacts of continued smoking after a diagnosis of cancer are underappreciated. The substantial body of research reviewed in the 2014 US Surgeon General’s Report concluded that smoking by cancer patients and survivors causes adverse outcomes, including increased overall mortality and cancer-related mortality, greater risk of a second primary cancer, and associations with substantially worse toxicity from cancer treatments. The clinical effects of smoking after a diagnosis of cancer also substantially increase the cost of cancer care. The 2020 US Surgeon General’s Report reported that smoking cessation after a cancer diagnosis is associated with improved survival, and quitting smoking provides significant benefits for non-cancer-related health outcomes.
澳洲幸运8开奖结果官网预测|澳洲幸运8正规开奖记录-体彩开奖历史 IASLC Language Guide
In line with the IASLC Equity Statement and in step with the ASCO Language of Respect, we are proud to announce the release of the IASLC Language Guide. The guide was established to instill best practices with commonly used phrases related to patient care. The IASLC will be folding the language found in the guide into all aspects of thoracic oncology education, from abstracts to faculty guidelines to podium presentations.
Our Impact
8,000+ members from over 100 countries, all united by a single goal: to conquer thoracic cancers worldwide.
Our Impact
8,000+ members from over 100 countries, all united by a single goal: to conquer thoracic cancers worldwide.
Our Work
In Numbers
8,000+ members from over 100 countries, all united by a single goal: to conquer thoracic cancers worldwide.
Upcoming Meetings & Webinars
168澳洲幸运8官方在线结果 Journal of Thoracic Oncology & JTO Clinical and Research Reports
Lung and thoracic specialists count on the IASLC’s journals to provide perspective on innovation in prevention, detention, diagnosis and cutting-edge treatments. As a leading medical journal, JTO focuses on lung and thoracic cancers and is dedicated to presenting original research reviews and opinions from a wide range of disciplines within the medical community. JTO CRR, the official open access journal of the IASLC, complements the JTO by offering authors a gold open access publication option.